BREASTEST plus
BREASTEST plus is a first-in-class blood test used alongside mammograms to help rule out breast cancer in women with dense breasts. Available in NSW & VIC.

BCAL Diagnostics is an Australian biotechnology company whose breast cancer screening blood test complements mammography.
bcaldiagnostics.comCrawled Nov 19, 2026
BREASTEST plus is a first-in-class blood test used alongside mammograms to help rule out breast cancer in women with dense breasts. Available in NSW & VIC.
Access BCAL Diagnostics resources: Information across shareholder services, clinical evidence and more.
The page lists news articles, interviews, and features about BCAL Diagnostics’ breast cancer blood test research.
Jayne Shaw, a UK-registered nurse and former Director of Nursing and CEO of private hospitals, co-founded BCAL Diagnostics and previously led Vision Group, an ASX-listed ophthalmic equity firm.
Jonathan Trollip, an Independent Non-Executive Director, brings over 30 years of global expertise in commercial, corporate governance, and law. He currently chairs ASX-listed entities, including Global Value Fund Ltd, Plato Income Maximiser Limited, and Spheria Emerging Companies Limited. Jonathan serves as a non-executive director for Kore Potash Limited on LSE, JSE, and ASX. His extensive […]
Michelle Blackwell leads BCAL Diagnostics’ product strategy as Chief Product Innovation Officer, bringing over two decades of experience in diagnostics, hospital pathology, and healthcare operations.
BCAL Diagnostics is an Australian biotech advancing early, non-invasive breast cancer diagnosis with a NATA-accredited LCMS lab. Founded 2010; ASX: BDX
BCAL Diagnostics develops non-invasive blood-based technologies for early cancer detection.
BCAL Diagnostics works with approved blood collection centres to enable access to cancer detection testing services, including:
BCAL Diagnostics provides contact options for general, clinician, media, and investor inquiries.
BCAL Diagnostics is developing a blood screening tool that is intended to be used alongside breast cancer screening methods.
BCAL Diagnostics focuses on improving cancer outcomes through non-invasive blood tests.
BCAL Diagnostics has filed a complaint against Microba Life Sciences regarding a proposed deal involving genetic signatures. The move challenges Microba’s planned acquisition of intellectual property related to genetic testing.
BCAL Diagnostics is progressing its blood-based tests for early breast cancer detection and multicancer screening ahead of a planned national launch. The company’s tests aim to identify cancer at earlier stages using liquid biopsy technology. No specific product names, funding details, or clinical trial results are mentioned in the update.
BCAL Diagnostics has finalized clinical validation for its **BREASTESTplus 2** blood test, designed to detect early-stage breast cancer regardless of breast tissue density. The company targets a **November 2026 commercial launch** in Sydney, Melbourne, and Brisbane, with plans for broader national distribution. The test represents an advancement in non-invasive breast cancer screening.
BCAL Diagnostics completes clinical validation for its **BREASTESTplus 2** blood test, a non-invasive breast cancer screening tool. The test detects biomarkers linked to early-stage disease, expanding access to risk assessment beyond traditional imaging. Regulatory approvals and commercial launch are targeted for **November 2026**, positioning it as a potential alternative for high-risk patients. The company now advances toward manufacturing and distribution partnerships.
BCAL Diagnostics secures a validation agreement with Sonic USA for its **Breastest V2** product. The deal aims to advance clinical validation of the breast cancer screening tool. BCAL Diagnostics lists on the ASX under the ticker **BDX**.